Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

被引:108
作者
Tse, KF
Novelli, E
Civin, C
Bohmer, FD
Small, D
机构
[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA
[3] Univ Jena, Max Planck Soc, Res Unit Mol Cell Biol, Fac Med, D-6900 Jena, Germany
关键词
FLT3; leukemia; inhibitors; tyrosine kinase;
D O I
10.1038/sj.leu.2402199
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
FLT3 is a member of the type III receptor tyrosine kinase (RTK) family. These receptors all contain an intrinsic tyrosine kinase domain that is critical to signaling. Aberrant expression of the FLT3 gene has been documented in both adult and childhood leukemias including AML, ALL and CML. In addition, 17-27% of pediatric and adult patients with AML have small internal tandem duplication mutations in FLT3. Patients expressing the mutant form of the receptor have been shown to have a decreased chance for cure. Our previous study, using a constitutively activated FLT3, demonstrated transformation of Ba/F3 cells and leukemic development in an animal model. Thus, there is accumulating evidence for a role for FLT3 in human leukemias. This has prompted us to search for inhibitors of FLT3 as a possible therapeutic approach in these patients. AG1296 is a compound of the tyrphostin class that is known to selectively inhibit the tyrosine kinase activity of the PDGF and KIT receptors. Since FLT3 is a close relative of KIT, we wanted to test the possible inhibitory activity of AG1296 on FLT3. In transfected Ba/F3 cells, AG1296 selectively and potently inhibited autophosphorylation of FL-stimulated wildtype and constitutively activated FLT3. Treatment by AG1296 abolished IL-3-independent proliferation of Ba/F3 cells expressing the constitutively activated FLT3 and thus, reversed the transformation mediated by activated FLT3. Inhibition of FLTB activity by AG1296 in cells transformed by activated FLT3 resulted in apoptotic cell death, with no deleterious effect on their parental counterparts. Addition of IL-3 rescued the growth of cells expressing activated FLTB in the presence of AG1296. This demonstrates that the inhibition is specific to the FLT3 pathway in that it leaves the kinases of the IL-3 pathway and other kinases further downstream involved in proliferation intact. Several proteins phosphorylated by the activated FLTB signaling pathway, including STAT 5A, STAT 5B and CBL, were no longer phosphorylated when these cells were treated with AG1296. The activity against FLT3 suggests a potential therapeutic application for AG1296 or similar drugs in the treatment of leukemias involving deregulated FLT3 tyrosine kinase activity and as a tool for studying the biology of FLTB.
引用
收藏
页码:1001 / 1010
页数:10
相关论文
共 78 条
  • [1] Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins
    Barber, DL
    Mason, JM
    Fukazawa, T
    Reedquist, KA
    Druker, BJ
    Band, H
    DAndrea, AD
    [J]. BLOOD, 1997, 89 (09) : 3166 - 3174
  • [2] TYRPHOSTINS INHIBIT PDGF-INDUCED DNA-SYNTHESIS AND ASSOCIATED EARLY EVENTS IN SMOOTH-MUSCLE CELLS
    BILDER, GE
    KRAWIEC, JA
    MCVETY, K
    GAZIT, A
    GILON, C
    LYALL, R
    ZILBERSTEIN, A
    LEVITZKI, A
    PERRONE, MH
    SCHREIBER, AB
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (04): : C721 - C730
  • [3] BIRG F, 1992, BLOOD, V80, P2584
  • [4] BRASEL K, 1995, LEUKEMIA, V9, P1212
  • [5] INHIBITION OF PLATELET-DERIVED GROWTH FACTOR-INDUCED MITOGENESIS AND TYROSINE KINASE-ACTIVITY IN CULTURED BONE-MARROW FIBROBLASTS BY TYRPHOSTINS
    BRYCKAERT, MC
    ELDOR, A
    FONTENAY, M
    GAZIT, A
    OSHEROV, N
    GILON, C
    LEVITZKI, A
    TOBELEM, G
    [J]. EXPERIMENTAL CELL RESEARCH, 1992, 199 (02) : 255 - 261
  • [6] SELECTIVE-INHIBITION OF THE PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION PATHWAY BY A PROTEIN-TYROSINE KINASE INHIBITOR OF THE 2-PHENYLAMINOPYRIMIDINE CLASS
    BUCHDUNGER, E
    ZIMMERMANN, J
    METT, H
    MEYER, T
    MULLER, M
    REGENASS, U
    LYDON, NB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) : 2558 - 2562
  • [7] Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias
    Carow, CE
    Levenstein, M
    Kaufmann, SH
    Chen, J
    Amin, S
    Rockwell, P
    Witte, L
    Borowitz, MJ
    Civin, CI
    Small, D
    [J]. BLOOD, 1996, 87 (03) : 1089 - 1096
  • [8] The TEL platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways
    Carroll, M
    Tomasson, MH
    Barker, GF
    Golub, TR
    Gilliland, DG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) : 14845 - 14850
  • [9] CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
    Carroll, M
    OhnoJones, S
    Tamura, S
    Buchdunger, E
    Zimmermann, J
    Lydon, NB
    Gilliland, DG
    Druker, BJ
    [J]. BLOOD, 1997, 90 (12) : 4947 - 4952
  • [10] CASTERAN N, 1994, CELL MOL BIOL, V40, P443